Medical network - August 25, according to flush the data as of August 24, biological medicine industry a total of 143 listed companies released 2017 annual report, total revenue of about 249.2 billion yuan in the first half of this year, to achieve net profit attributable to shareholders of listed companies a total of about 25.44 billion yuan.Of the 73 listed companies, the net profit for the first six months was over 100 million yuan.
According to the national bureau of statistics data show that in January 2017 - June, our country medicine manufacturing industry to realize the main business income is 1.4516 trillion yuan, profit of 159.6 billion yuan, year-on-year growth of 12.18% and 16.26% respectively, compared with 2016, the income growth and profit growth are improved.
The development of traditional Chinese medicine industry has also attracted the attention of the market."The method of traditional Chinese medicine" and "the strategic plan for development of Chinese medicine (2016-2030)" and other laws, regulations and policies related to the ground, for the healthy development of the future of traditional Chinese medicine industry provides a good dividend policy and the support.According to flush the data, as of August 24, a-share biological medicine industry listed companies of earnings during the first half of the top ten, there are six from traditional Chinese medicine industry, two biological products company, 2 jahwa medicine listed companies.
Yunnan baiyao and baiyunshan listed companies posted net profit of more than 1 billion yuan in the first half.Bai yunshan's semi-annual performance report for 2017 showed that the company realized revenue of 11.115 billion yuan, up 2.38 percent year on year.Net profit attributable to shareholders of listed companies was 1.58 billion yuan, up 39.23 percent year on year.
In addition, the net income of the four listed companies belonging to the listed companies of donga gum, tianshili, huarun sanjiu, and step pharma were 900 million yuan, 756 million yuan, 740 million yuan and 678 million yuan respectively.
The 11 listed companies have doubled their performance
According to huanshun data, 110 of the listed pharmaceutical bio-listed companies published in the semi-annual report of 2017 have seen growth.Among them, 11 listed companies, including zhifei biology, xingpu medical, garden biology and modern pharmaceutical, have seen a double growth.
It is reported that after the adjustment of the category 2 vaccine industry, the related listed companies have a new development period.In the semi-annual report of the 2017 annual report of zhifei biology, the company realized operating revenue of 445 million yuan, an increase of 142.01 percent year-on-year.The net profit attributable to shareholders of listed companies was 170 million yuan, a year-on-year increase of 1326.96%.The company's main business revenue comes from second class vaccine sales.During the reporting period, the uncertainty factors caused by last year's vaccine industry events are gradually being eliminated, the new policies of the industry have gradually been implemented, and sales of the second type vaccine have been gradually restored.
Watson biological 2017 semi-annual report released during the reporting period, the company net profit attributable to shareholders of listed companies - 43.0162 million yuan, a year earlier loss-mitigation 118.8856 million yuan, up 73.43% from a year earlier, in the second quarter from the first quarter loss-mitigation 15.5823 million yuan.
Moreover, the transformation and development of listed companies have also changed the performance.During the reporting period, the company realized operating income of 128.65 million yuan, down 25.76 percent from a year earlier.Net profit attributable to shareholders of listed companies of 81.1036 million yuan, up 486.47% from a year earlier, after deducting non-recurring gains and losses attributable to shareholders of listed companies net profit of 36.2417 million yuan, increased by 224.64% from a year earlier.
The 21 companies sell gross margins of over 80%
The pharmaceutical industry's sales gross margin is also the focus of the market.According to huanshun data, 21 listed companies have a gross profit margin of over 80%.Among them, seven listed companies, including wubibio, beida pharmaceutical, haite, shutai god, zhenghai biology, zhifei biology and kanghong pharmaceutical, have a gross profit margin of over 90%.
I wu biological main business for biopharmaceutical class, has licensed products include "dust mites drops" (trade name: chang di) and "dust mites skin prick diagnostic kits" (trade name: chang points).The gross margin of these two products is close to 97%, which is the first in the industry.
In the first half of this year, the core product of bayda pharmaceutical company realized sales revenue of about 498 million yuan, the operating cost was 22032,000 yuan, and the gross profit margin was 95.58%.Beida pharmaceutical industry are introduced, the company independent research and development of products, belong to the national first class new drugs for ek, is also China's first with independent intellectual property rights of small molecules targeting anticancer drugs, ek 2012 for his products by ministry of science and technology identified as the national strategic innovation.
|
